Sunitinib effectiveness and safety as first line treatment in metastatic renal cell carcinoma, in the Costa Rican population

Abstract

Aim: Tyrosine kinase inhibitors are part of the armamentarium to treat metastatic renal cell carcinomas (mRCC). Costa Rica has approved sunitinib in the first line setting. The authors conducted a retrospective study to address the effectiveness and safety profile of sunitinib in our population in terms of overall survival (OS) and progression free survival (PFS).

Methods: The authors analyzed all patients who were treated with sunitinib diagnosed with mRCC in the three National Hospitals (Hospital Mexico, Hospital San Juan de Dios, and Hospital Calderon Guardia) from February 2007 to June 2015. Demographics, safety profile, and efficacy (OS and PFS) were obtained from medical records. OS and PFS were calculated using the Kaplan Meier method and a Cox Proportional Model Analysis was used when OS and PFS were compared in subset of patients.

Results: Seventy-seven patients were included; mean age was 58.9 years. Fifty-four patients were male (70.1%). The most common histologic type was clear cell carcinoma (87%), followed by papillary (9.1%) and chromophobe (2.0%) types. Median OS was 21.0 months [95% confidence interval (CI): 13.42-28.58]. Median PFS was 13.7 months (95% CI: 11.24-16.16). Patients aged 65 years or older experienced worse PFS and OS than younger patients (median PFS: 8.2 vs. 17.6 months; P = 0.011) (median OS: 19.0 vs. 29.0 months; P = 0.022). Sunitinib was well tolerated and no serious side effects were reported.

Conclusion: This is the first study in Central America showing that sunitinib, first line, in mRCC is as effective as reported in pivotal clinical trials and expanded use studies in terms of PFS and OS.

Keywords

Sunitinib / renal cell carcinoma / effectiveness / Latin America / Costa Rica

References

[1] Rini BI,Escudier B.Renal cell carcinoma..Lancet2009;373:1119-32

[2] Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr. [Accessed on 16/04/2016]

[3] Patard JJ,Rioux-Leclercq N,Ficarra V,De La Taille A,Artibani W,Lobel B,Chopin DK,Wood CG,Figlin RA,Pantuck AJ.Prognostic value of histologic subtypes in renal cell carcinomas: a multicenter experience..J Clin Oncol2005;23:2763-71

[4] Siegel R,Jemal A.Cancer statistics, 2012..CA Cancer J Clin2012;62:10-29

[5] Ljungberg B,Hanbury DC,Kuczyk MA,Patard JJ,Sinescu IC.EAU guidelines on renal cell carcinoma: the 2010 update..Eur Urol2010;58:398-406

[6] Van PH,Cadeddu JA,Janetschek G,Laguna MP,Montorsi F,Ukimura O.Treatment of localised renal cell carcinoma..Eur Urol2011;60:662-72

[7] Subotic S,Bachmann A.Surgical treatment of localised renal cancer..Eur Urol S2012;11:60-5

[8] Minardi D,Santoni M,Scartozzi M,Muzzonigro G.Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature..Curr Urol Rep2015;16:3

[9] Gossage L,Maher ER.VHL, the story of a tumour suppressor gene..Nat Rev Cancer2015;15:55-64

[10] Fung SMC.Overall survival analysis in metastatic clear cell renal cell Carcinoma, in the Costa Rican Health Care System. (CCSS) Data from 2007 to 2012..Waxapa2013;9:5-10

[11] Gan HK,Knox JJ.Sunitinib in solid tumors..Expert Opin Investig Drugs2009;18:821-34

[12] Motzer RJ,Bukowski RM,George DJ,Redman BG,Merchan JR,Ginsberg MS,Kim ST,Michaelson MD.Sunitinib in patients with metastatic renal cell carcinoma..JAMA2006;295:2516-24

[13] Motzer RJ,Tomczak P,Bukowski RM,Negrier S,Pili R,Garcia-del-Muro X,Solska E,Thompson JA,Chen I,Figlin RA.Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma..J Clin Oncol2009;27:3584-90 PMCID:PMC3646307

[14] National Comprehensive Cancer Network (NCCN ver 2.2016), Kidney Cancer. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. [Accessed on 09/05/2016]

[15] Escudier B,Schmidinger M,Patard JJ,Eisen T.Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up..Ann Oncol2014;25 Suppl 3:iii49-56

[16] Motzer RJ,Tomczak P,Bukowski RM,Oudard S,Szczylik C,Chen I,Baum CM.Sunitinib versus interferon alfa in metastatic renal-cell carcinoma..N Engl J Med2007;356:115-24

[17] Gore ME,Porta C,Bjarnason GA,Hariharan S,Haanen J,Vrdoljak E,Mainwaring P,Yuan J.Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial..Lancet Oncol2009;10:757-63

[18] Gore ME,Porta C,Bjarnason GA,Lee SH,Castellano D,Schöffski P,Hawkins RE,Kim TM,Eberhardt WE,Fly K,Lechuga MJ,Bukowski R.Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma..Br J Cancer2015;113:12-9 PMCID:PMC4647545

[19] Smaletz O.Current management and future directions in the treatment of advanced renal cell carcinoma - a Latin American perspective: 10 years in review..Int Braz J Urol2015;41:835-43 PMCID:PMC4756959

[20] Barrios CH,Chacón M,Sajben P.Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma..Onco Targets Ther2016;9:5839-45 PMCID:PMC5045222

[21] Hutson TE,Rini BI,Larkin JM,Barrios CH,Lin X,Martell B,Motzer RJ.Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma..Br J Cancer2014;110:1125-32

[22] Miyake H,Harada K.Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan..Med Oncol2014;31:978

[23] Castellano D,Korves C,Neary M,Bellmunt J.Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain..Expert Opin Drug Saf2013;12:455-63

[24] Ansari J,Fernando K,James ND.Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience..Oncol Rep2010;24:507-10

[25] Vrdoljak E,Mardiak J,Leyman S,Sajben P.Central and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial..Pathol Oncol Res2015;21:775-82

[26] Abdel-Rahman O.Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature..Cri Rev Oncol Hemat2015;94:238-50

[27] Lee JL,Lim HY,Lee SH,Lee DH,Song C,Kim CS.Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma..Ann Oncol2012;23:2108-14

[28] Shi HZ,Li CL.Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma..Asia Pac J Clin Oncol2015;11:328-33